Ishaan Gupta

Sagar Singh Gwal, Rajan, Suyash Devgan et al.

Lung adenocarcinoma (LUAD) is a subtype of non-small cell lung cancer (NSCLC). LUAD with mutation in the EGFR gene accounts for approximately 46% of LUAD cases. Patients carrying EGFR mutations can be treated with specific tyrosine kinase inhibitors (TKIs). Hence, predicting EGFR mutation status can help in clinical decision making. H&E-stained whole slide imaging (WSI) is a routinely performed screening procedure for cancer staging and subtyping, especially affecting the Southeast Asian populations with significantly higher incidence of the mutation when compared to Caucasians (39-64% vs 7-22%). Recent progress in AI models has shown promising results in cancer detection and classification. In this study, we propose a deep learning (DL) framework built on vision transformers (ViT) based pathology foundation model and attention-based multiple instance learning (ABMIL) architecture to predict EGFR mutation status from H&E WSI. The developed pipeline was trained using data from an Indian cohort (170 WSI) and evaluated across two independent datasets: Internal test (30 WSI from Indian cohort) set, and an external test set from TCGA (86 WSI). The model shows consistent performance across both datasets, with AUCs of 0.933 (+/-0.010), and 0.965 (+/-0.015) for the internal and external test sets respectively. This proposed framework can be efficiently trained on small datasets, achieving superior performance as compared to several prior studies irrespective of training domain. The current study demonstrates the feasibility of accurately predicting EGFR mutation status using routine pathology slides, particularly in resource-limited settings using foundation models and attention-based multiple instance learning.

Samarth Bhatia, Yukti Makhija, Sneha Jayaswal et al.

As the second wave in India mitigates, COVID-19 has now infected about 29 million patients countrywide, leading to more than 350 thousand people dead. As the infections surged, the strain on the medical infrastructure in the country became apparent. While the country vaccinates its population, opening up the economy may lead to an increase in infection rates. In this scenario, it is essential to effectively utilize the limited hospital resources by an informed patient triaging system based on clinical parameters. Here, we present two interpretable machine learning models predicting the clinical outcomes, severity, and mortality, of the patients based on routine non-invasive surveillance of blood parameters from one of the largest cohorts of Indian patients at the day of admission. Patient severity and mortality prediction models achieved 86.3% and 88.06% accuracy, respectively, with an AUC-ROC of 0.91 and 0.92. We have integrated both the models in a user-friendly web app calculator, https://triage-COVID-19.herokuapp.com/, to showcase the potential deployment of such efforts at scale.

Yukti Makhija, Samarth Bhatia, Shalendra Singh et al.

Many countries are now experiencing the third wave of the COVID-19 pandemic straining the healthcare resources with an acute shortage of hospital beds and ventilators for the critically ill patients. This situation is especially worse in India with the second largest load of COVID-19 cases and a relatively resource-scarce medical infrastructure. Therefore, it becomes essential to triage the patients based on the severity of their disease and devote resources towards critically ill patients. Yan et al. 1 have published a very pertinent research that uses Machine learning (ML) methods to predict the outcome of COVID-19 patients based on their clinical parameters at the day of admission. They used the XGBoost algorithm, a type of ensemble model, to build the mortality prediction model. The final classifier is built through the sequential addition of multiple weak classifiers. The clinically operable decision rule was obtained from a 'single-tree XGBoost' and used lactic dehydrogenase (LDH), lymphocyte and high-sensitivity C-reactive protein (hs-CRP) values. This decision tree achieved a 100% survival prediction and 81% mortality prediction. However, these models have several technical challenges and do not provide an out of the box solution that can be deployed for other populations as has been reported in the "Matters Arising" section of Yan et al. Here, we show the limitations of this model by deploying it on one of the largest datasets of COVID-19 patients containing detailed clinical parameters collected from India.